Abstract
The pharmacodynamic characteristics of the stimulus effects of the hallucinogensd-LSD and (−)DOM were investigated in the rat. The stimulus control induced by (−)DOM (0.56 mg/kg) was significantly less stable at the 15-min pretreatment time than at the 75-min pretreatment time. In addition, (−)DOM (0.8 mg/kg) produced a time-dependent substitution for the LSD stimulus in LSD trained subjects (0.1 mg/kg, 15-min pretreatment time). As pretreatment times were increased, the substitution of (−)DOM (0.8 mg/kg) for the LSD stimulus increased, culminating in a maximal level of 99.5% LSD-appropriate responding at the 75-min pre-treatment time. A dose-response relationship for the substitution of (−)DOM (75-min pretreatment time) for the LSD stimulus, indicated that 0.2 mg/kg (−)DOM was the minimum dose which elicited greater than 90% LSD-appropriate responding. LSD (0.32 mg/kg, 15-min pretreatment time) fully substituted for (−)DOM in the (−)DOM trained subjects (0.56 mg/kg, 75-min pretreatment time). These findings suggest that the pharmacodynamic parameters ofd-LSD and (−)DOM-induced stimulus control differ. The time of onset for the stimulus effects of (−)DOM is markedly longer than that of LSD in the rat.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Appel JB, White FJ, Holohean AM (1982) Analyzing mechanisms of hallucinogenic drug action with drug discrimination procedures. Neurosci Biobehav Rev 6:529–536
Balster RL (1990) Perception of drug effects. In: Berkeley MA comparative perception vol 1: basic mechanisms. Stebbins WG (eds) Wiley NY., pp 127–154
Brady JV, Hienz RD, Ator NA (1990) Stimulus functions of drugs and the assessment of abuse liability. Drug Dev Res 20:231–249
Burt PR, Creese I, Snyder SH (1976) Binding interactions of lysergic acid and diethylamide related agents with dopaminergic receptors in brain. Mol Pharmacol 12:631–638
Colpaert FC (1984) Cross-generalization with LSD and yohimbine in the rat. Eur J Pharmacol 102:541–544
Colpaert FC, Niemegeers CJE, Janssen PAJ (1979) In vivo evidence of partial agonist activity exerted by purported 5-HT antagonists. Eur J Pharmacol 58:505–509
Colpaert FC, Niemegeers CJE, Janssen PAJ (1982) A drug discrimination analysis of lysergic acid diethylamide (LSD): In vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenpirone, a LSD antagonist. J Pharmacol Exp Ther 221:206–214
Cunningham KA, Appel JB (1987) Neuropharmacological reassessment of the discriminative stimulus properties of lysergic acid diethylamide (LSD). Psychopharmacology 91:67–73
Freedman DX, Boggan WO (1982) Biochemical pharmacology of psychotomimetics. In: Hoggmeist F, Stile G (eds) Psychotropic agents: handbook of experimental pharmacology vol 55, part 3. Springer Berlin, pp 57–88
Friedman RL, Barrett RJ, Sanders-Bush E (1984) Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites. J Pharmacol Exp Ther 223:628–635
Glennon RA (1990) Do hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 3:509–517
Glennon RA, Hauck AE (1985) Mechanistic studies on DOM as a discriminative stimulus. Pharmacol Biochem Behav 23:937–941
Glennon RA, Rosecrans JA, Young R (1982) The use of the drug discrimination paradigm for studying hallucinogenic agents. In: Colpaert FC, Slangen JL (eds) Drug discrimination: applications in CNS pharmacology. Elsevier Biomedical Press, Amsterdam, pp 69–96
Glennon RA, Rosecrans JA, Young R (1984) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289–376
Hirschhorn ID, Winter JC (1971) Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli. Psychopharmacologia 22:64–71
Hollister LE, MacNicol MF, Gillespie HK (1969) An hallucinogenic amphetamine analog (DOM) in man. Psychopharmacology 14:62–73
Holmberg G, Gershon S (1961) Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacology 2:93–106
Huang JT (1972) Biochemical and pharmacological study of 2,5-dimethoxy-4-methylamphetamine and analogs. PhD dissertation, University of Texas Graduate School of Biomedical Sciences, Houston
Jacobsen E (1963) The clinical pharmacology of the hallucinogens. Clin Pharmacol Ther 4:480–503
Kulig K (1990) Emergency aspects of drug abuse: LSD. Emer Med Clin NA 3:551–558
Lowy MT, Meltzer HY (1988) Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. Biol Psychiatry 23:818–828
Meibach RC, Maayani S, Green JP (1980) Characterization and radioautography of [3H]LSD binding by rat brain slices in vitro: the effect of 5-hydroxytryptamine. Eur J Pharmacol 67:371–382
Palumbo PA, Winter JC (1992) Stimulus effects of ibogaine in rats trained with yohimbine, DOM or LSD. Pharmacol Biochem Behav 43:1221–1226
Palumbo PA, Winter JC (1994) Interactions of clozapine with the stimulus effects of DOM and LSD. Pharmacol Biochem Behav 49:115–120
Parati EA, Zanardi P, Cocchi J, Muller EE (1980) Neuroendocrine effects of quipazine in man in healthy state or with neurological disorders. J Neural Transm 47:293–297
Pazos A, Cortes R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II Serotonin-2 receptors. Brain Res 346:231–249
Pollard JC, Bakker C, Uhr L, Feurfile DF (1960) Controlled sensory input: a note on the technique of drug evaluation with a preliminary report on a comparative study of Sernyl, psilocybin, and LSD. Comp Psychiatry 1:377–380
Sanders-Bush E, Burris KD, Knoth K (1988) Lysergic acid diethylamide and 2,5-dimethoxy-4-methamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924–928
Shulgin A (1973) Stereospecific requirements for hallucinogens. J Pharm Pharmacol 25:271–272
Shulgin A, Shulgin A (1991) The chemical story. In: Joy D (ed) PIHKAL. Transform Press, Burkeley, California pp 453–924
Shulgin A, Shulgin A, Jacob P (1986) A protocol for the evaluation of new psychoactive drugs in man. Methods Find Exp Clin Pharmacol 8:313–320
Silverman PB, Ho BT (1978) Stimulus properties of DOM: commonality with other hallucinogens. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Elsevier, North Holland Biomedical Press, Amsterdam, pp 189–198
Silverman PB, Ho BT (1980) The discriminative stimulus properties of 2,5-dimethoxy-4-methylamphetamine (DOM): differentiation from amphetamine. Psychopharmacology 68:209–215
Snyder SA, Faillace L, Hollister L (1968) 2,5-Dimethoxy-4-methylamphetamine (STP): A new hallucinogenic drug. Science 158:669–670
Tilson HA, Baker TG, Gylys JA (1975) A comparison of the discriminative stimulus properties ofR-2,5-dimethoxy-4-methylamphetamine [R(-)DOM] and S-amphetamine in the rat. Psychopharmacology 44:229–239
White FJ, Appel JB (1982) Training dose as a factor in LSD-saline discrimination. Psychopharmacology 76:20–25
Winter JC (1978) Drug-induced stimulus control. In: Blackman D, Sanger J, (ed) Contemporary research in behavioral pharmacology. Plenum Press, New York, pp 209–238
Winter JC (1979) Quipazine-induced stimulus control in the rat. Psychopharmacology 60:265–269
Winter JC (1994) The stimulus effects of serotonergic hallucinogens in animals. In: Lin GC, Glennon RA (ed) Hallucinogens, an update. NIDA Monograph, USPGO (in press)
Author information
Authors and Affiliations
Additional information
This study was supported in part by U.S. Public Health Service grant DA 03385 [J.C.W., R.A.R.], by National Research Service Award MH 10567 [D.F.], and by a fellowship from Schering-Plough Research Institute [D.F.]. Animals used in these studies were maintained in accordance with the “Guide for Care and Use of Laboratory Animals” of the Institute of Laboratory Animal Resources, National Research Council
Rights and permissions
About this article
Cite this article
Fiorella, D., Palumbo, P.A., Rabin, R.A. et al. The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents. Psychopharmacology 119, 239–245 (1995). https://doi.org/10.1007/BF02246166
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246166